275 related articles for article (PubMed ID: 37959808)
21. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
[TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates in HER2-positive breast cancer.
Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
[TBL] [Abstract][Full Text] [Related]
23. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
24. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
Li XF; Liu CF; Rao GW
Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
[TBL] [Abstract][Full Text] [Related]
28. Cleavable linkers in antibody-drug conjugates.
Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
[TBL] [Abstract][Full Text] [Related]
29. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
31. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
32. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
33. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
34. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
36. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
37. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
38. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
40. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
